Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Bortezomib is a proteasome inhibitor with remarkable preclinical and clinical antitumor activity in multiple myeloma (MM) patients. The initial rationale for its use in MM was inhibition of nuclear factor (NF)-κB activity by blocking proteasomal degradation of inhibitor of κBα (IκBα). Bortezomib inh...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hideshima, Teru, Ikeda, Hiroshi, Chauhan, Dharminder, Okawa, Yutaka, Raje, Noopur, Podar, Klaus, Mitsiades, Constantine, Munshi, Nikhil C., Richardson, Paul G., Carrasco, Ruben D., Anderson, Kenneth C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2009
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2721785/
https://ncbi.nlm.nih.gov/pubmed/19436050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-01-199604
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados